Switzerland’s Axmed Secures $6M Gates Foundation Grant To Expand Access To Medicines
Feb 18, 2026 | By Kailee Rainse

Axmed a Swiss HealthTech company, has been awarded €5 million ($6 million) in non-dilutive grant funding from the Gates Foundation to expand access to high-quality, affordable medicines in low- and middle-income countries through its B2B procurement and integrated logistics platform.
SUMMARY
- Axmed a Swiss HealthTech company, has been awarded €5 million ($6 million) in non-dilutive grant funding from the Gates Foundation to expand access to high-quality, affordable medicines in low- and middle-income countries through its B2B procurement and integrated logistics platform.
This grant follows a previous €4.2 million ($5 million) award from the Foundation. Alongside additional support from Founderful Ventures, Axmed has now raised a total of €11 million ($13 million) in funding to date.
Founded in 2023 Axmed is a technology-enabled B2B marketplace and logistics platform connecting buyers, manufacturers and distributors to streamline procurement and delivery of essential medicines across low- and middle-income countries.
Read Also - Stockholm’s Hybridity Raises €2M To Accelerate AI-Driven Compliance
RECOMMENDED FOR YOU
Stablecoin Infrastructure Startup BVNK Gets Strategic Investment From Visa
Kailee Rainse
May 7, 2025
UnameIT partnership news – UnameIT Enters into Strategic Partnership with Main Capital Partners
Kailee Rainse
Jan 8, 2025
By combining pooled demand, data-driven sourcing, and integrated international logistics, Axmed reduces costs, improves supply reliability, and expands access to quality-assured healthcare products. The company maintains a regional headquarters in Nairobi, Kenya.
The new funding will accelerate expansion across Africa and support procurement programmes across multiple therapeutic areas, including family planning and malaria, serving mothers, children and underserved populations over the next 12–18 months.
Since launch, Axmed has delivered over 1,800 metric tonnes of healthcare products in 2025, reaching 4.2 million patients up from 750,000 in 2024 while achieving 12x year-on-year revenue growth and a 70% repeat purchase rate. The platform generates 30–35% cost savings for customers through demand aggregation, price transparency, and coordinated international logistics.
Axmed plans to operate in 20+ countries by the end of 2026, targeting 50 million patients within three years and over 100 million within five, positioning itself as a core infrastructure layer for medicines procurement in underserved markets.
“This funding allows us to scale what already works while we bring in aligned long-term capital,” says Emmanuel Akpakwu, Founder and CEO of Axmed. “With the continued support of the Gates Foundation, our focus is disciplined execution at scale: strengthening procurement systems, improving affordability, and ensuring high-quality medicines reliably reach the people who depend on them.”
About Axmed
Axmed is creating a technology-first infrastructure for global health procurement and supply, simplifying access to essential medicines. By combining data-driven sourcing, pooled demand, and integrated logistics, the platform makes procurement more efficient, insightful and impactful, accelerating access to quality-assured healthcare for underserved populations worldwide.healthcare for underserved populations worldwide.







